Evommune (EVMN) Accumulated Expenses (2024 - 2026)

Evommune's (EVMN) quarterly Accumulated Expenses came in at $4.7 million in Q1 2026, down 4.05% on a QoQ basis from $4.9 million in Q4 2025.

Evommune (EVMN) Accumulated Expenses (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Accumulated Expenses data on file, last reported at $4.7 million in Q1 2026.

On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.9 million, up 35.77% from the prior year.
Accumulated Expenses for Q1 2026 stood at $4.7 million, down from $4.9 million in the prior quarter.
Over the last five years, Accumulated Expenses for EVMN reached as high as $4.9 million in Q4 2025 and fell as low as $2.9 million in Q3 2025.
Historically, Accumulated Expenses has averaged $4.0 million across 3 years, with a median of $4.2 million in 2024.
On a YoY basis, Accumulated Expenses climbed as much as 35.77% in 2025 and fell as far as 35.77% in 2025.
Year by year, Accumulated Expenses stood at $3.6 million in 2024, then jumped by 35.77% to $4.9 million in 2025, then fell by 4.05% to $4.7 million in 2026.
Per Business Quant data, the three most recent Accumulated Expenses figures were $4.7 million in Q1 2026, $4.9 million in Q4 2025, and $2.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Evommune	381.48 Mn	170.02 Mn	-

Download Data